Seres Therapeutics appoints Paul Biondi to its Board of Directors

– USA, MA –  Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Paul Biondi, Executive Partner at Flagship Pioneering, to its Board of Directors.

Noubar Afeyan, Ph.D., a co-founder of Seres and CEO of Flagship Pioneering, is stepping down after serving on the Board since the founding.

“I look forward to partnering with Paul, a talented and deeply experienced corporate executive, to advance Seres’ pipeline as we work to bring transformative new medicines to patients,” said Eric Shaff, President and CEO of Seres. “I would also like to express our gratitude to Noubar for his fundamental contributions to Seres. Through Flagship’s founding of Seres and its advancement of microbiome technologies, Noubar and Flagship have made a profoundly important impact catalyzing this new therapeutic segment. Flagship has been an important Seres shareholder, and we are glad to be able to continue to benefit from Noubar’s counsel.”

“Paul brings strategic acumen, deep business development expertise and a wealth of biotech experience ahead of a potentially transformational period for the Company. I look forward to his contributions to Seres’ efforts to advance the burgeoning field of microbiome therapeutics,” said Stephen Berenson, Chairman of the Board of Seres and Managing Partner of Flagship Pioneering.

About Paul Biondi

Prior to joining Flagship, Mr. Biondi had a 17-year tenure at Bristol-Myers Squibb, most recently as Senior Vice President of Strategy and Business Development, where he had enterprise-wide responsibility for establishing and evolving BMS’s strategy and pursuing strategic transactions to access external innovation and strengthen BMS’s portfolio. Previously, he held a series of leadership roles within BMS’s R&D organization overseeing strategy, portfolio and project management and clinical and business operations. Earlier in his career, he was a strategic consultant with Mercer Management Consulting.

“Seres is leading the development of microbiome therapeutics, a very promising new area of medicine. The Company has been at the forefront of implementing the highest quality clinical studies and of building field-leading drug discovery and manufacturing capabilities. I am honored to be joining the Board as the Company enters an exciting and potentially transformative period with two near-term, late-stage clinical readouts, as well as a number of additional earlier-stage programs progressing forward,” said Mr. Biondi.

He holds a bachelor’s degree from Dartmouth College and an MBA from the J.L. Kellogg School of Management at Northwestern University.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma and SER-301 for ulcerative colitis.

For more information: https://www.serestherapeutics.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.